1,5-anhydro-D-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice

被引:28
作者
Ahrén, B [1 ]
Holst, JJ
Yu, SK
机构
[1] Univ Lund, Malmo Univ Hosp, Dept Med, SE-20502 Malmo, Sweden
[2] Univ Copenhagen, Panum Inst, Dept Endocrinol & Metab, DK-2200 Copenhagen, Denmark
[3] Danisco Biotechnol, Copenhagen, Denmark
关键词
insulin secretion; glucose elimination; 1,5-anhydro-D-fructose; glucagon-like peptide-1; (mouse);
D O I
10.1016/S0014-2999(00)00261-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Besides being degraded to glucose-6-phosphate and to free glucose, glycogen is degraded by alpha-1,4-glucan lyase to 1,5-anhydro-D-fructose. We examined the influence of 1,5-anhydro-D-fructose on glucose-stimulated insulin secretion in vivo and in vitro in mice. When administered together with i.v. glucose (1 g/kg), 1,5-anhydro-D-fructose did not affect (at 0.2 g/kg) or inhibited (at 1 g/kg) insulin secretion without affecting glucose elimination. When incubated with isolated islets, 1,5-anhydro-D-fructose at < 16.7 mmol/l, did not affect glucose (11.1 mM)-stimulated insulin secretion but inhibited insulin secretion at 16.7 mmol/l. When given through a gastric gavage (150 mg/mouse) together with glucose (150 mg/mouse), 1,5-anhydro-D-fructose increased glucose tolerance and insulin secretion. Furthermore, I,5-anhydro-D-fructose potentiated the increase in plasma levels of the gut hormone, glucagon-like peptide-1 (GLP-1). We therefore conclude that when given enterally, but not parenterally, 1,5-anhydro-D-fructose increases glucose tolerance in mice by increasing insulin secretion due to increased plasma levels of GLP-1. The sugar may therefore be explored for increasing endogenous GLP-1 secretion in the treatment of type 2 diabetes. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 33 条
  • [1] Ahrén B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO
  • [2] 2-K
  • [3] A NEW LOOK AT THE BIOGENESIS OF GLYCOGEN
    ALONSO, MD
    LOMAKO, J
    LOMAKO, WM
    WHELAN, WJ
    [J]. FASEB JOURNAL, 1995, 9 (12) : 1126 - 1137
  • [4] MUSCARINIC STIMULATION MAINTAINS IN-VIVO INSULIN-SECRETION IN RESPONSE TO GLUCOSE AFTER PROLONGED HYPERGLYCEMIA
    BALKAN, B
    DUNNING, BE
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1995, 268 (02) : R475 - R479
  • [5] FUNGAL ENZYMIC ACTIVITY DEGRADING 1,4-ALPHA-D-GLUCANS TO 1,5-D-ANHYDROFRUCTOSE
    BAUTE, MA
    BAUTE, R
    DEFFIEUX, G
    [J]. PHYTOCHEMISTRY, 1988, 27 (11) : 3401 - 3403
  • [6] Analysis of 1,5-anhydro-D-fructose, microthecin, and 4-deoxy-glycero-hexo-2,3-diulose in algae using gas chromatography mass spectrometry in selected ion monitoring mode
    Broberg, A
    Kenne, L
    Pedersén, M
    [J]. ANALYTICAL BIOCHEMISTRY, 1999, 268 (01) : 35 - 42
  • [7] Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
    Deacon, CF
    Knudsen, LB
    Madsen, K
    Wiberg, FC
    Jacobsen, O
    Holst, JJ
    [J]. DIABETOLOGIA, 1998, 41 (03) : 271 - 278
  • [8] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS
    DEACON, CF
    NAUCK, MA
    TOFTNIELSEN, M
    PRIDAL, L
    WILLMS, B
    HOLST, JJ
    [J]. DIABETES, 1995, 44 (09) : 1126 - 1131
  • [9] PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice
    Filipsson, K
    Pacini, G
    Scheurink, AJW
    Ahrén, B
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 274 (05): : E834 - E842
  • [10] GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions
    Gutniak, MK
    Larsson, H
    Sanders, SW
    Juneskans, O
    Holst, JJ
    Ahren, B
    [J]. DIABETES CARE, 1997, 20 (12) : 1874 - 1879